Measurement of airway inflammation in asthma

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 1, 2002, Pages 25-32

  Wilson, N ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NITRIC OXIDE;

ASTHMA; BREATH ANALYSIS; BRONCHUS BIOPSY; CORRELATION FUNCTION; DIAGNOSTIC APPROACH ROUTE; DISEASE CONTROL; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFLAMMATION; REVIEW;

EID: 0036136895     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200201000-00005     Document Type: Review

References (93)

1. Inflammatory markers in bronchoalveolar lavage and bronchial biopsy in asthma during remission
2. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness
3. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics
4. Evidence for different subgroups of difficult asthma in children
5. Induced sputum in children: Feasibility, repeatability, and relation of findings to asthma severity
6. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children
7. Exhaled markers of pulmonary disease
8. Inflammatory markers in clinical practice
9. Asthma: From bronchoconstriction to airways inflammation and remodeling
10. The pathology of asthma: Brief review
11. Biopsy markers of airway inflammation and remodelling
12. Monitoring central and peripheral airway inflammation in asthma
13. Cellular events in the bronchi in mild asthma and after bronchial provocation
14. Safety and ethics of bronchoscopy and endobronchial biopsy in difficult asthma
15. Ultrastructural examination of bronchial biopsy specimens from children with moderate asthma
16. Serum measurement of eosinophil cationic protein in the management of asthma
17. Inflammatory events in asthma: An expanding equation
18. Serum levels of eosinophil cationic protein and eosinophils in asthmatic children during a course of prednisolone therapy
19. Significance of the eosinophil cationic protein/eosinophil count ratio in asthmatic patients: Its relationship to disease severity
20. Serum levels of eosinophilic cationic protein (ECP), myeloperoxidase (MPO), lipid peroxidation products, interleukin (IL)-5 and interferon (IFN)-gamma in children with bronchial asthma at acute asthma attack and remission
21. Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawal
22. Eosinophil cationic protein (ECP)in school children living in a mountainous area of Norway: A population-based study of ECP as a tool for diagnosing asthma in children with reference values
23. Is serum ECP level helpful in determining discontinuation of inhaled corticosteroid therapy in asthmatic children?
24. Eosinophil and mast cell parameters in children with stable moderate asthma
25. Serum eosinophil cationic protein (ECP) and eosinophil protein X (EPX) in childhood asthma: The influence of atopy
26. Can eosinophil-derived proteins be used to diagnose or to monitor childhood asthma?
27. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children
28. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN): Time and temperature dependent spontaneous release in vitro demands standardized sample processing
29. Use of induced sputum cell counts to investigate airway inflammation in asthma
30. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study
31. Induced sputum cell counts: Their usefulness in clinical practice
32. Success and safety of sputum induction in the clinical setting
33. Between-observer repeatability of sputum differential cell counts: Influence of cell viability and squamous cell contamination
34. Reproducibility of measurements of exhaled NO, and cell count and cytokine concentrations in induced sputum
35. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood
36. Noninvasive assessment of airway inflammation in children: Induced sputum, exhaled nitric oxide, and breath condensate
37. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
38. Induced sputum: Validity of fluidphase IL-5 measurement
39. Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods
40. Induced sputum cell counts in healthy adults
41. Exhaled and nasal nitric oxide measurements: Recommendations
42. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999: This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999
43. A simple flow-driven method for online measurement of exhaled NO starting at the age of 4 to 5 years
44. FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr
45. Correlation between reversibility of airway obstruction and exhaled nitric oxide levels in children with stable bronchial asthma
46. FE(NO): Relationship to exhalation rates and online versus bag collection in healthy adolescents
47. Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma
48. Exhaled carbon monoxide in childhood asthma
49. Exhaled pentane levels in acure asthma
50. Elevation of exhaled ethane concentration in asthma
51. Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: A new marker of oxidative stress
52. Increased nitrotyrosine in exhaled breath condensate of patients with asthma
53. Hydrogen peroxide in exhaled air of healthy children: Reference values
54. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma
55. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma
56. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma
57. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation
58. Relationship between induced sputum cell counts and fluid-phase eosinophil cationic protein and clinical or physiologic profiles in mild asthma
59. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma
60. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma
61. Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low-dose allergen challenge in atopic asthmatics
62. Exhaled nitric oxide: Is it really a good marker of airway inflammation in bronchial asthma?
63. Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma
64. The relationship between airways inflammation and asthma severity
65. Exhaled nitric oxide levels correlate with measures of disease control in asthma
66. Asthma severity and inflammation markers in children
67. Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: Eosinophil, ECP, and cytokine levels in induced sputum
68. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids
69. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal
70. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids
71. Potential masking effects of salmeterol on airway inflammation in asthma
72. Relation between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone
73. Exacerbations of asthma without sputum eosinophilia
74. Airway inflammation is present during clinical remission of atopic asthma
75. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma
76. Association of sputum parameters with clinical and functional measurements in asthma
77. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma
78. Acute anti-inflammatory effects of inhaled budesonide in asthma: A randomized controlled trial
79. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients
80. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids
81. Combined use of exhaled nitric oxide and airway hyperresponsiveness in characterizing asthma in a large population survey
82. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients
83. Changes in sputum eosinophils predict loss of asthma control
84. Asthma severity, recommended changes of inhaled therapy and exhaled nitric oxide in children: A prospective, blinded trial
85. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma
86. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment
87. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study
88. Expired nitric oxide and airway obstruction in asthma patients with an acute exacerbation
89. Changes in sputum cell counts after exposure to occupational agents: What do they mean?
90. Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide
91. Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics
92. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults
93. Heterogeneity of therapeutic responses in asthma